PT 141

PT-141 peptide benefits

PT‑141, also known as bremelanotide, is a synthetic cyclic heptapeptide structurally derived from α‑melanocyte‑stimulating hormone (α‑MSH).

It acts primarily as an agonist at melanocortin receptors MC3R and MC4R, in the central nervous system [1]. By doing so, it activates hypothalamic pathways, resulting in downstream signals that influence sexual arousal and associated neurobiologic responses.

Mechanistic target of PT-141

PT‑141 exerts its effect through binding and activation of melanocortin receptors, especially within the hypothalamus.

Evidence from animal studies indicates that systemic administration of PT‑141 induces penile erection and activates hypothalamic neurons, as shown by increased c‑Fos immunoreactivity [1].

By working on sexual arousal and desires in the brain, PT-141’s mechanism of action differs from phosphodiesterase‑5 (PDE-5) inhibitors, which cause peripheral vasodilation.

Instead, PT‑141 stimulates arousal via central neurochemical cascades, including increased dopamine release in key brain regions governing sexual function. This also means combining PT-141 with PDE5 inhibitors can have additive effects. Also, PT-141 is more effective in females than PDE5.

PT-141 and erectile dysfunction

Male erectile function

Across preclinical and clinical studies, PT-141 demonstrated the ability to increase sexual arousal in both men and women, with dose-dependent efficacy and an acceptable safety profile in the controlled research setting.

A randomized, double-blind, placebo-controlled clinical trial was combined with preclinical animal studies to investigate the effects of PT-141 on sexual dysfunction [1].

Preclinical results suggests that PT-141:

• Activated MC3 and MC4 melanocortin receptors in the central nervous system.
• Produced sexual arousal behaviors in rodents without directly affecting the vascular system.

The parallel clinical trial found that intranasal PT-141 up to 20 mg,  produced significant improvements in erectile function compared to placebo. The erectile response rates were dose-dependent, with higher doses achieving a significant increase in rigidity and duration of erection (p < 0.05).

Adverse events were generally mild to moderate, with the most common being dose-dependent, transient nausea and flushing.

Phase I data shows that subcutaneous doses of PT‑141 (10 mg, 20 mg) increased duration of base rigidity ≥ 80% in healthy males.

Phase 2A results indicated significantly longer durations at the 20 mg dose, with common adverse events including flushing and nausea.

Co-administration of PT‑141 (7.5 mg) plus sildenafil (25 mg) enhanced erectile response over sildenafil alone [2].

PT-141 and female libido

Two identical Phase 3 RCTs enrolled a total of 2,449 premenopausal women with hypoactive sexual desire disorder (HSDD). 1,247 participants were included in the safety population, and 1,202 in the modified intent-to-treat efficacy analysis [3].

Participants were randomized 1:1 to receive either bremelanotide 1.75 mg or placebo administered subcutaneously on an as-needed basis over 24 weeks.

Bremelanotide administration resulted in:

• Increases in Female Sexual Function Index (FSFI) desire domain scores versus placebo (p < 0.01)
• Reductions in Female Sexual Distress (FSDS-DAO) scores (p < 0.01)

The most common adverse events (≥10% in both studies) were nausea, flushing, and headache. Most events were mild to moderate in severity.

These findings support the potential of bremelanotide in modulating sexual desire in female populations.

PT-141 safety and side effect profile

Preclinical and clinical evidence indicate that PT‑141 (bremelanotide) is generally safe in research settings, with most adverse events being mild to moderate and transient.

Adverse events

The most frequently reported side effects include nausea, flushing, and headaches [4].

Cardiovascular effects

PT-141 is associated with transient and mild cardiovascular effects, including:

• Blood pressure elevation ( ~3 mm Hg systolic and 2 mm Hg diastolic)
• Heart rate reduction

These effects peaked within a few hours and returned to baseline within approximately 8–10 hours.

Importantly, there was no net increase in overall myocardial workload [5].

Pigmentation

Activation of melanocortin receptors can contribute to hyperpigmentation on the face, gums, and breasts.

This was rare with dosing protocols in research settings (fewer than eight doses per month). However, this became more common with daily consecutive dosing [6].

Rare events

A single case of acute hepatitis was reported in a participant after approximately 20 subcutaneous doses over one year.

Significant elevations in aminotransferases and mild hyperbilirubinemia, resolved after discontinuation of PT‑141 [6].